Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan Sells 115,290 Shares

Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan sold 115,290 shares of Regulus Therapeutics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $145,265.40. Following the completion of the transaction, the chief executive officer now owns 222,572 shares of the company’s stock, valued at approximately $280,440.72. This trade represents a 34.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Regulus Therapeutics Stock Performance

RGLS opened at $1.27 on Thursday. Regulus Therapeutics Inc. has a one year low of $1.08 and a one year high of $3.79. The company has a fifty day moving average price of $1.52 and a 200-day moving average price of $1.59.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, equities research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp bought a new stake in Regulus Therapeutics during the second quarter valued at approximately $352,000. Rhumbline Advisers purchased a new stake in shares of Regulus Therapeutics during the 2nd quarter valued at $136,000. Renaissance Technologies LLC lifted its holdings in shares of Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 42,600 shares during the last quarter. SG Americas Securities LLC purchased a new position in Regulus Therapeutics in the third quarter worth $33,000. Finally, Creative Planning bought a new position in Regulus Therapeutics in the third quarter valued at $26,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Regulus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.